Deal value in Egyptian healthcare is built on regulatory execution. Navigating the Egyptian Drug Authority (EDA), the Unified Procurement Authority (UPA), import restrictions, and facility licensing requires local precision. We help multinational corporations, local manufacturers, and investors align transactions with these rules.
Our experience includes Valeant's acquisition of Amoun Pharmaceutical, valued at over USD 800 million, a USD 330 million divestment for Bristol Myers Squibb, the sale of Eli Lilly's Egyptian manufacturing facility alongside a USD 290 million supply agreement, and the EGP 1.4 billion medical manufacturing joint venture between ECMI and JMS. We also act in the sector's disputes, including linked criminal and civil proceedings for Amoun Pharmaceutical.
Regulatory Affairs & Market Entry: advising on the legal requirements or the Egyptian Drug Authority (EDA) registration, pricing, and import licensing for pharmaceuticals and medical devices.
Commercial & Operational Agreements: drafting and negotiating complex supply, distribution, agency, and toll manufacturing arrangements.
Strategic Transactions: advising on M&A, joint ventures, divestments, and private equity investments across the healthcare sector.
Clinical Research: advising on the legal and regulatory framework of clinical trials
Infrastructure & Dispute Resolution: handling EPC construction agreements for manufacturing plants and resolving high-stakes industry disputes.
STAY UPDATED WITH NEWS SUBSCRIBE TO OUR NEWSFEED
This website contains general information on legal and related matters and should not be interpreted as legal advice. Adsero – Ragy Soliman & Partners (“Adsero”) does not warrant or guarantee the quality, accuracy or completeness of any information on this website…
